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Antithymocyte globulin in cadaver kidney transplantation: A
randomized trial based on T-cell monitoring. The influence of
horse antihuman thymocyte globulin (ATG) on renal allograft
survival was assayed between March 1977 and August 1978. Fif-
ty consecutive patients were randomly assigned to the treatment
or the control group. Patients in both groups received azathio-
prine and prednisolone. ATG was added in the experimental
group. The daily dosage was such as to maintain the rosette-
forming cell (RFC) level at 10% of baseline values. The number
of renal failure episodes (RFE's) was significantly lower in the
experimental group during the period (1 month) ATG was given
than it was in the control group during that same period of time.
Two years after transplantation, kidney survival was 79% in the
ATG group and 52% in the control group. The amount of steroids
necessary to control RFE's was significantly lower in the ATG
group. The dosages of ATG used in the experimental group were
relatively small (average daily dose, 3.08 0.26 mg/kg of body
wt), and adverse reactions were mild. Blood tolerance was ex-
cellent. T-cell monitoring thus appears to be an effective method
in evaluating the daily dosage of ATG.
Globuline anti-thymocytaire dans Ia transplantation du rein de
cadavre: Etude randomisée l'ondée sur l'étude de cellules T.
L'influence de la globuline anti-thymocytes humaine (ATG) sur
Ia survie d'allogreffe rénale a été évaluée entre Mars 1977 et
Aoflt 1978. Cinquante malades consécutifs ont été affectés au ha-
sard au groupe traité ou au groupe contrôle. Les malades des
deux groupes ont recu de l'azathioprine et de Ia prednisolone.
L'ATG a été ajoutée dans le groupe experimental. La dose quot-
idienne a été ajustée de telle sorte que les cellules formant des
rosettes (RFC) soient maintenues a 10% des valeurs basales. Le
nombre d'épisodes d'insuffisance rénale (RFE) a été signifi-
cativement inférieur durant Ia période d' un mois pendant la-
quelle I'ATG a été donnée. Deux ans après La transplantation la
survie de Ia greffe était de 79% dans Ic groupe ATG et de 52%
dans Ic groupe contrôle. La quantité de stéroide nécessaire a
contrôler les episodes de rejet a été significativement inférieure
dans le groupe ATG. Les doses d'ATG utilisées dans le groupe
experimental ont été relativement faibles (dose quotidienne
moyenne 3,08 0,26 mg/kg de poids corporel) et les effets see-
ondaires ont été raisonnables. La tolerance sanguine a été ex-
cellente. La mesure des cellules T paralt étre une méthode effi-
cace dans la determination de la posologie quotidienne de
I'ATG.
Received for publication October 29, 1979
and in revised form April 30, 1980
0085-2538/81/0019-0438 $01.40
© 1981 by the International Society of Nephrology
438
Since the first reports in the early 1960's, cortico-
steroids and azathioprine have been considered as
the most efficient nonspecific systemic immuno-
suppression drugs. They are still the basic immuno-
suppressive regimen used in renal transplantation
although results achieved are far from satisfactory.
Since the initial enthusiasm provoked by the ex-
perimental work of Woodruff and Anderson in 1963
[1] and Monaco, Wood, and Russel in 1965 [2] and
by the first human trial reported by Starzl et al in
1967 [3], opinions about the effectiveness of anti-
lymphocyte serum in kidney transplantation have
been varied and sometimes contradictory. Such a
diversity of opinion is not surprising since many dif-
ferent products are included under the general name
of antilymphocyte serum (ALS) or globulin (ALG).
For example, different immunized animals are used,
such as horses, goats, and rabbits. Immunizing lym-
phocytes may be drawn from circulating blood,
lymph nodes, thoracic duct, thymus, spleen, or
even from lymphocyte culture. In addition, the pro-
duction process, the level of purification, and the
antibody titer also differ from one serum sample to
another. As a result, it is impossible to form an
opinion on the value of ALS or ALG in general.
This explains the conflicting conclusions on the ef-
fectiveness of ALS drawn from reasonably con-
trolled series.
The efficacy of antithymocyte globulin (ATG) as
an adjunctive agent has been suggested recently by
Kountz et al [4], and the use of a T-cell count to
monitor the daily dose of ATG required by a given
patient for an accurate therapeutic level has been
recommended by Cosimi et al [5]. This report is part
of an international multicenter study to determine
the actual effectiveness of ATG in prolonging kid-
ney graft survival and to assess the possibility of
ATG dose determination by T-cell counts.
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Methods
Between March 1977 and August 1978, 50 con-
secutive cadaveric kidney recipients were randomly
assigned to the treatment or control group. This as-
signment was made for the 50 patients on the basis
of random-number tables before starting the study.
Physicians in charge of the patients were not aware
of the list kept at the Upjohn Company. A positive
ATG skin test was the only reason for exclusion,
and only one patient was thus excluded from the
ATG group.
Preparation of antihuman thymocyte globulin
(ATG). The ATG used in this study was prepared by
the Upjohn Company for a larger multi-institutional
study. Preparation of Upjohn's ATG has already
been published elsewhere in detail [6]. Immunizing
lymphocytes were selectively purified from individ-
ual thymus glands obtained during thoracic surgery
and then pooled. Horses were immunized by a stan-
dard multiple injection procedure, which includes
the formation of antibodies with high rosette-inhibi-
tion titers. For purification, plasma is absorbed with
human erythrocyte stroma to reduce hemagglutinin
titers and with IgG-free human plasma proteins to
remove antibodies to human plasma proteins with-
out contaminating the final product with human
IgG. Lot 17-9 13 was used in the present study. The
various assay data performed on this lot were re-
ported by Wechter et al [6].
Iminunosuppression protocols. In both groups,
kidney transplant recipients received our standard
immunosuppression regimen [7], that is, 3 mg/kg of
body wt per day of oral prednisolone sodium meta
sulfobenzoate, progressively tapered off in 10
weeks to reach the maintenance level of 0.25 mg/kg
of body wt per day. Methyiprednisolone sodium
succinate (40 mg., i.v.), subtracted from the total
daily prednisolone dose, was given immediately pri-
or to each ATG infusion in the treatment group. Af-
ter an initial dosage of 500 to 1250 mg according to
body weight, daily ATG dosages in this group were
determined by the daily level of rosette-forming
cells (RFC), with the aim of maintaining this level at
10% of baseline values. Baseline RFC values were
determined immediately prior to transplantation,
before any immunosuppressive therapy was insti-
tuted.
Sheep E rosette technique. This technique has
been described elsewhere [8] and is only summa-
rized here. Lymphocytes were isolated on a Ficoll-
Hypaque gradient. Untreated sheep red blood cells
(SRBC's) were added in a radio of 30:1. The mix-
ture was incubated for 30 mm at 3° C in Hanks' me-
dium with 25% fetal calf serum added, centrifuged
at X200g for 5 mm, and then left for 2 hours at 4° C.
The cells were then gently resuspended for 1 to 2
mm. Rosettes were defined as lymphocytes with at
least four SRBC's attached. Results were expressed
as (1) the absolute numbers of lymphocytes that
formed rosettes in the blood and (2) their percent-
age of pretransplantation baseline values. This tech-
nique regularly gives 71.5% 0.8 of RFC in normal
subjects. ATG was administered i.v. every day for 2
weeks, then every other day for another 2 weeks.
The use of a placebo in the control group was not
considered useful because the drop of RFC level
was patent and constant in patients receiving ATG.
Patient selection. All patients considered for
transplantation were between 15 and 50 years of
age. They were all typed for HLA A and B locus
and checked for anti-HLA antibody at regular inter-
vals before transplantation. The 50 kidneys used
originated from various harvesting centers. They
were all preserved in Collins solution.
Criteria for graft evaluation. The primary crite-
rion for success was the survival of patient and
graft. Another criterion was the number and the se-
verity of rejection episodes. In fact, as there are no
reliable criteria for defining a rejection episode, we
analyzed the incidence of renal failure episodes
(RFE's). The patients considered to have RFE's
were those in whom the serum creatinine, after an
initial improvement, stabilized at an abnormal level
or increased by more than 0.3 mg/dl for at least 2
consecutive days. The first day of the RFE was that
on which serum creatinine first rose, and the end
was the first day of a spontaneous decrease in
serum creatinine, provided the decrease lasted for
at least 48 hours. Many nonimmunologic accidents
were thus included in our study, but by this method
not a single clinically patent rejection episode was
overlooked. Other criteria were onset and duration
of RFE's, total amount of steroids required in both
groups, and tolerance of ATG as assessed by ad-
verse reaction or increased frequency of infectious
episodes in patients receiving ATG.
Results
As shown in Table 1, sex, age, total ischemia
time of the graft, HLA compatibility, previous pre-
immunization, and blood transfusion status of pa-
tients were comparable in both groups.
Occurrence of renal failure episodes (RFE's).
The number of patients with RFE's was significant-
ly higher in the control than it was in the ATG group
(Table 2). This difference between the two groups
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Table 1. Compatible status of the two groups studied
Total No. of No. of
No. of Mean age ischemia time compatible preimmunized
Groupsa females yr hr grafts recipients
No. of recipients
without previous
blood transfusion
ATG(N= 24) 6 34.7 1.7 20.5 0.6 16 4 1
Control (N = 25) 9 30.9 1.5 19.7 0.5 18 3 2
a ATG group was given antihuman thymocyte globulin.
b A compatible graft is three or four HLA A and B antigens shared by the donor and the recipient.
Table 2. Incidence of renal failure episodes (RFE's)
1st mo.
Reversible RFEsa reversible RFE's'
No. of
Groups patients no. F no. F no.
Irreversible
graft failurea
F
Control 25 35 1.40 16 0.64 12 0.48
ATG5 24 19 0.79 7 0.29 5 0.21
P = 0.02 <0.02 < 0.05
a F is frequency per patient.
ATG group was given antihuman thymocyte globulin.
was observed only during the first month following
transplantation; that is, during the time ATG was
given. During that time, RFE's occurred in 7 pa-
tients in the ATG group versus 16 in the control
group. No differences were observed after the first
month. Similar results were observed for the total
number of RFE's in each group (Table 2 and Fig. 1).
Duration of renal failure episodes (RFE's). Al-
though there was a lower incidence of RFE's in the
treated group, the duration of RFE's (8.4 1.6
days) was similar to that of the control group (7.7
1.3 days).
Kidney and patient survival. Death occurred in 40
of the 25 control patients and in 2 of the 24 ATG
patients. Up to 2 years, kidney survival was signifi-
cantly worse in the control group (12 failures) than
it was in the ATG group (5 failures) (P <0.05) (Fig.
2).
Kidney function. The level of kidney function
during the first month following transplantation was
also superior in the treated group (Fig. 3).
Amount of steroids. The amount of steroid re-
quired by our protocol during the first month was
fairly high. The mean daily doses received by pa-
tients in the control group was 3 0.18 mg/kg of
body wt per day during the first month and 1.88
0.10 mg/kg/day during the first 3 months. Because
of the lower incidence of RFE's in the ATG group,
the mean daily doses of steroids received by these
patients were significantly lower than the dose re-
ceived by control group patients. During the first
month following transplantation, patients were giv-
en 3.0 0.18 mg/kg/day of oral prednisolone versus
2.58 0.09 mg/kg/day for ATG patients (P <0.05).
During the first 3 months, prednisolone doses were
1.88 0.10 mg/kg/day versus 1.32 0.06 mg/kg'
day, respectively, in control and ATG patients (P <
0.001).
Tolerance of antihuman thymocyte globulin
(ATG): Side effects and adverse reactions. A rela-
Week of onset
Fig. 1. Total number and date of onset of renal failure episodes
in ATG (antihuman thymocyte globulin) and control groups.
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Fig. 3. Mean serum creatinine concentrations for control vs. pa-
tients given ATG (antihuman thymocyte globulin).
tively small amount of ATG was required to main-
tain the RFC blood level at approximately 10% of
baseline values. The average total dose was 4389
409 mg, with a minimum of 2013 mg and a maximum
of 9630 mg. The average daily dose was 3.08 0.26
mg/kg of body wt. ATG was frequently discontin-
ued because of a low percentage of RFC, and the
average number of doses given during the 28 treat-
ment days was 14 0.81.
Of 24 patients, 9 demonstrated 15 adverse reac-
tions attributed to ATG (Table 3). Only one reac-
tion, an epidermal necrolysis, was severe. Of the
six fever episodes, three were observed 5 to 10 days
after ATG was withdrawn. They were assumed to
be related to ATG only because no other cx-
planation could be found. ATG was discontinued in
only two cases, because of a rise in antihorse globu-
lin antibody titer.
Blood tolerance. The white blood cell count at
the end of each of the first 4 weeks was similar in
control and in treated patients (Table 4). Similarly,
no decrease in platelet count was observed in pa-
tients treated with ATG.
Bacterial infections. Bacterial infections oc-
curred in 36 out of 49 patients; that is, 17 of 25 in the
control group and 19 of 24 in the ATG group. This
difference is not statistically significant. When uri-
nary infections are excluded, the number of infect-
ed patients are again similar: 14/25 and 12/24 in con-
trol and experimental groups, respectively. Staph y-
lococcus aureus was the most commonly
encountered infectious agent, in 11 of the 25 control
patients and in 12 of the 24 ATG patients.
Blood level of rosette-forming cells. Because of
extreme values that distort the mean, our analysis
compares the medians. Statistical comparison by
the Wilcoxon Rank Sum test shows that ATG pa-
tients had a lower number of RFC per mm3 at all the
time periods (Table 5). The comparison between
Table 5 and Table 6 shows that the occurrence of a
rejection episode did not alter RFC blood level,
Adverse reactionsa
Week of onset
1 2 3 4 5 6 7 Total
Arthralgia
Chills
Epidermal necrolysis,
toxic
Fever
Rise in antihorse
globulin antibody
1
1
1 1
2
3
2
2 1 1
4
2
1
6
2
following transplantation
Groups Days
WBC counta
(x 10)
Platelet counta
(x 10)
Control 7
14
21
28
8.5
7.8 0.8
6.1 0.8
6.2± 1.2
259 18
231 16
215 23
271 1
ATG 7
14
21
28
11.1 1.1
8.7 0.9
6.0 0.7
5.4 0.5
239 17
207 22
214 19
207 17
a Values are the means SEM.
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Fig. 2. Actuarial kidney survival in ATG (antihuman thymocyte
globulin) vs. control. Differences between the two curves are sta-
tistically significant (P < 0.01).
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Table 3. Adverse reactions to antihuman thymocyte globulin
(ATG) in the experimental group
ATG
a Total no. of patients demonstrating adverse reactions was 9.
Table 4. WBC and platelet counts during the first month
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Table 5. Total number of rosette-forming cells (per mm3) before transplantation and during the first month after surgery
in both groups of patients
Before
transplantation Day 1 Day 2 Day 3 Day 4 Day 5 Day 7 Day 10 Day 14 Day 21 Day 28
Group receiving antihuman thymocyte giohulin (ATG)
N 24 23 23 22 23 23 23 23 23 22 19
Mean 918 112 155 160 136 141 147 170 254 218 269
Median 880 55 137 142 112 102 111 119 143 195 219
Minimum 359 13 36 25 21 17 33 16 62 53 36
Maximum 2120 660 508 572 357 567 578 797 1538 685 1104
N 25 25 23 25
Control
25 25 25 24 24 20 22
Mean 1138 519 329 376 353 323 308 568 365 392 440
Median 1050 325 304 294 244 285 279 269 297 321 342
Minimum 364 4 98 74 48 55 69 73 94 110 168
Maximum 2112 4987 838 933 1156 1312 884 5628 1973 879 1096
Table 6. Blood concentration of rosette-forming cells (per mm3)
during the first rejection episodes occurring within the first 28
days after transplantation
Groups N
Before rejection
episodesa
During first 5 days
of treatmenta
Control 14 210(96 to 752) 239(142 to 1589)
ATG 6 105(13to129) 121 (85to179)
P <0.003 <0.002
a Numbers in parentheses denote the minimum and maximum
values.
which remains lower in the ATG than in the control
group. Surprisingly, RFC values were slightly high-
er during the first 5 days of treatment than they
were during the pretreatment period.
Discussion
Even though 10 years have elapsed since the first
human trial with antithymocyte globulin was report-
ed in kidney transplantation [9], remarkably little is
known about its effectiveness. This is partly due to
the lack of well-controlled studies. Studies are fre-
quently biased by variations either in the type of
antisera used or in the selection of patients [10, 11].
The more recent and correctly conducted analysis
of ALG treatment in connection with kidney trans-
plantation showed either no influence on allograft
survival [12], a limited action on selected groups of
patients [13], a shorter duration of rejection epi-
sodes [14], or a reduction in the number of patients
experiencing rejection episodes and an increase in
graft survival [15, 16]. In our study, ATG was used
in an open randomized clinical investigation as an
adjunctive agent to the established two-drug regi-
men with azathiopnne and steroids. Experimental
and control groups were very similar, and the ma-
jority of transplantations were performed with a
three or four HLA match.
As frequently reported in most studies on ALG or
ATG efficacy [9, 11, 15, 17], we observed a statisti-
cally significant decrease in the frequency of revers-
ible renal failure episodes in treated patients. This
was the consequence of a lower frequency during
the first month following transplantation; that is,
during the period when ATG was administered.
Thereafter, the frequency of renal failure episodes
was similar in both groups, and no rebound was
demonstrated. This was also the case in other re-
ports using different ATG lots on a protocol of 14
daily doses [17]. Such a decrease in renal failure
episodes is probably the consequence of the effica-
cy of ATG, which prevented the occurrence of the
true rejection episodes. It is difficult to know wheth-
er the remaining renal failure episodes might be re-
lated to a rejection process that was not affected by
ATG. They are more likely to be related to a latent
nonimmunologic extrarenal con tplication.
We have already shown that high doses of
steroids given immediately following trans-
plantation are unable to prevent the occurrence of
rejection episodes [19]. This is confirmed in the
present study. In this regard, ATG associated with
steroids was much more effective. Whether ATG
alone would have done as well remains to be dem-
onstrated because corticosteroid treatment has
been said to potentiate the effect of ALG [201. Nev-
ertheless, the ATG used in this study (Upjohn, lot
17913) has proved to be a potent immuno-
suppressive adjunct to azathioprine and steroids. If
steroids in kidney transplantation do not act as an
immunosuppressive but mainly as an anti-
inflammatory drug [18], it is worthwhile to evaluate
the ability of ATG in association with a nonsteroid
antiinflammatory drug to prevent graft rejection.
The present results, as well as all other works with
ALG or ATG, have one potential flaw, as it is not
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likely that ATG from different laboratories, or even
from different lots, will have a similar influence on
graft survival. So far, the same lot (17913) has not
been used by other groups in a similar protocol.
Shield et a! [21] had good results in a prospective
randomized study evaluating its effectiveness for
reversal of established rejection.
Toxicity of ATG was very low, and even fever,
which is commonly reported in other series [5, 11],
was infrequent here. The susceptibility of patients
receiving ALG or ATG to systemic infection re-
mains a critical question [16, 22]. Our data show,
however, no increased incidence of bacterial, viral,
or fungal infection in the treated group when com-
pared with the control patients, and similar findings
have already been reported by others [15, 23-25].
But some studies show a trend toward more fungal
and viral infections in ATG-treated patients than in
controls [5]. The only severe and life-threatening
complication that might probably be attributed to
ATG in our study was an epidermal necrolysis
(LyeIl's syndrome). It occurred during the first
week of treatment and was followed by a significant
rise in antihorse globulin antibody level in the
serum of the patient. Nevertheless, Staphylococcus
aureus was cultured in the blood during the same
period. It is thus not possible to conclude whether
epidermal necrolysis was the consequence of the
staphylococcus infection or of an allergic reaction
to ATG.
Finally, the use of ATG was not harmful for our
patients. This may be due to a low toxicity of the lot
used, to the relatively small amount used in each
patient as a consequence of daily dose monitoring,
or to careful use of the drug (pretransplantation skin
test and routinely performed antihorse globulin
antibody dosage). In fact, ATG was withdrawn only
twice because of a rise in antihorse globulin anti-
body.
It is generally accepted that T lymphocytes (and
eventually B lymphocytes) will be depleted from
the central lymphoid organs by ALG or ATG treat-
ment. But it is clear that T-cell blood level cannot
be significantly related with kidney graft outcome or
with the occurrence of rejection episodes [12, 26].
The data reported in Tables 5 and 6 show no altera-
tion of RFC blood level at the onset of a renal fail-
ure episode when compared with the median RFC
level of the overall population of patients. It could
be stated, however, as suggested by Cosimi et al
[5], that no rejection episodes were observed in the
ATG patients in whom the RFC level was main-
tained as close as possible to 10% of baseline values
and that the remaining renal failure episodes occur-
ring in ATG-treated patients were not the con-
sequence of a rejection process. Whatever the ex-
planation, RFC count cannot be considered a re-
liable monitor of the rejection phenomenon.
On the other hand, the wide range among patients
of the ATG dosage required to achieve an RFC
blood level of 10% of baseline values suggests a
wide variability in patient responsiveness to a given
ATG preparation. Adjustment of RFC levels to 10%
of baseline values is of course arbitrary. It has been
shown, however, that the risk of severe infections is
much greater when the absolute RFC count is be-
low 50/mm3 [5]. In addition, the precise adjustment
of RFC level is far from easy, as shown in Table 5.
The 10% RFC level thus appears to be a good safety
factor. The favorable results observed in our study
with much smaller amounts of ATG than that used
in most other series [4, 13] are contradictory with
the data reported by Geis et al [27]. On the other
hand, they confirm the view of Cosimi et al [5] that a
"therapeutic level of immunosuppression can be
accurately achieved in individual patients by mon-
itoring T-cell counts during therapy." Whether sim-
ilar results would have been obtained by giving con-
tinuous low doses instead of adjusting the ATG
dose of RFC level has not been considered in this
work, but it has already been shown by Butt et al
[15] with another ATG lot from the same manufac-
turer that fixed low doses of ATG were ineffective,
whereas fixed high doses improved graft survival.
The mean daily doses of ATG used in our study
were in fact lower than the low doses (250 mg/day)
used by Butt et al.
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